Identification, frequency, activation and function of CD4+ CD25(high)FoxP3+ regulatory T cells in children with juvenile idiopathic arthritis.
The aim of the study was to test the frequency of CD4+ CD25(high)FoxP3 regulatory T cells in JIA patients and to assess their activation status and functional activity. The study involved 12 children with JIA and 35 healthy control subjects. PBMC were stained with monoclonal antibodies (anti-CD25, anti-CD4, anti-CD127, anti-CD69, anti-CD71, and anti-FoxP3). The samples were evaluated using flow cytometer. CD4+ CD25- and CD4+ CD25+ cells were isolated by negative and positive selection with magnetic microbeads. CD4+ CD25+ and CD4+ CD25- cells were cultured separately and co-cultured (1:1) with or without PHA. The percentage of Tregs in JIA patients was significantly decreased in comparison with controls (median, 3.2 vs. 4.6; P = 0.042). Relative fluorescence intensities of FoxP3 were higher in JIA patients than in controls (median, 9.1 vs. 6.8). The percentage of activated Tregs (CD71+) was significantly higher in JIA patients in comparison with controls (median, 6.5 vs. 2.8; P = 0.00043). CD4+ CD25+ cells derived from JIA patients and controls were anergic upon PHA stimulation, while CD4+ CD25- cells showed intensive proliferative response. The proliferation rate of CD4+ CD25- cells stimulated by PHA was decreased in co-cultures. In JIA patients, the inhibition of proliferation of CD4+ CD25- cells by CD4+ CD25+ cells was 37.9%, whereas in controls it was significantly lower (55.7%, P = 0.046). JIA patients had statistically lower percentage of Tregs in peripheral blood compared to controls. CD4+ CD25+ cells sorted from peripheral blood of JIA patients had statistically lower ability to suppress CD4+ CD25- cell proliferation in comparison with cells obtained from controls.
Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, ul. Marszalkowska 24, 00-576 Warsaw, Poland. anna.stelmaszczyk-emmel@wum.edu.pl
Anna
A
Stelmaszczyk-Emmel
Teresa
T
Jackowska
Lidia
L
Rutkowska-Sak
Maria
M
Marusak-Banacka
Maria
M
Wąsik
D000293:Adolescent; D000328:Adult; D001171:Arthritis, Juvenile / Q000276:immunology*; D015415:Biomarkers / Q000378:metabolism; D015704:CD4 Antigens / Q000378:metabolism*; D016022:Case-Control Studies; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D002648:Child; D018920:Coculture Techniques; D005260:Female; D005434:Flow Cytometry; D051858:Forkhead Transcription Factors / Q000378:metabolism*; D006801:Humans; D018189:Immunomagnetic Separation; D016130:Immunophenotyping / Q000379:methods; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000494:pharmacology; D011044:Poland; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology*; D055815:Young Adult
D015415:Biomarkers; D015704:CD4 Antigens; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; C508017:IL2RA protein, human; D053645:Interleukin-2 Receptor alpha Subunit; D010835:Phytohemagglutinins
Nat Immunol. 2003 Apr;4(4):337-42
12612581
J Rheumatol. 2009 Sep;36(9):2017-24
19648312
J Immunol. 2004 May 15;172(10):6435-43
15128835
Rheumatology (Oxford). 2006 Oct;45(10):1210-7
16571607
Arthritis Rheum. 1986 Feb;29(2):274-81
3485433
Nat Immunol. 2003 Apr;4(4):330-6
12612578
Arthritis Rheum. 2004 Sep;50(9):2775-85
15457445
Clin Exp Immunol. 2005 May;140(2):360-7
15807863
Arthritis Rheum. 2008 Mar;58(3):875-87
18311821
Eur J Immunol. 2002 Jun;32(6):1621-30
12115645
J Rheumatol. 2004 Feb;31(2):390-2
14760812
Immunology. 2002 Jun;106(2):190-9
12047748
Nat Rev Immunol. 2008 Jul;8(7):523-32
18566595
Lancet. 2007 Mar 3;369(9563):767-778
17336654
J Exp Med. 2006 Jul 10;203(7):1693-700
16818676
Lancet. 1998 Mar 28;351(9107):969-73
9734957
Nat Immunol. 2007 Mar;8(3):277-84
17220892
J Immunol. 2017 Feb 1;198(3):981-985
28115586
Arthritis Res Ther. 2009;11(1):216
19291269
Semin Immunol. 2004 Apr;16(2):89-98
15036232
Trends Immunol. 2006 Dec;27(12):541-4
17045841
J Exp Med. 2004 Aug 2;200(3):277-85
15280421
J Exp Med. 2001 Jun 4;193(11):1303-10
11390437
Nature. 2007 Feb 15;445(7129):766-70
17220876
Cancer Res. 2008 Jul 1;68(13):4998-5003
18593896
Clin Immunol. 2005 Apr;115(1):10-8
15870015
J Exp Med. 2002 Nov 18;196(10):1335-46
12438424
J Exp Med. 2005 Jun 6;201(11):1793-803
15939793
Rheum Dis Clin North Am. 1991 Nov;17(4):891-905
1767079
Cell Immunol. 2008 May-Jun;253(1-2):92-101
18649874
J Exp Med. 2006 Jul 10;203(7):1701-11
16818678
Cell Immunol. 1993 Oct 15;151(2):437-50
8402947
J Immunol. 2001 Aug 1;167(3):1245-53
11466340
Eur J Immunol. 2003 Jan;33(1):215-23
12594850
J Exp Med. 2001 Jun 4;193(11):1285-94
11390435
Eur J Immunol. 1992 Apr;22(4):993-9
1348033
Arthritis Res Ther. 2004;6(4):R335-46
15225369
J Clin Oncol. 2006 Mar 1;24(7):1169-77
16505437
J Microbiol Immunol Infect. 2008 Feb;41(1):78-87
18327431